Fenofibrate PK Fact Sheet

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

Details

Generic Name	Fenofibrate
Trade Name	Antara®, Cholib®, Fenoglide®, Fenomax®, Lipanthyl®, Lipantil®, Lipidil®, Lipofen®, Tricor®, Triglide®, *also available as generic products.*
Class	PBC agents
Molecular Weight	360.8
Structure	

Summary of Key Pharmacokinetic Parameters

Linearity/non-linearity	Not reported Concentrations stable during continuous therapy.
Steady state	9 days
Plasma half-life	20 h
Cmax	2450 ng/L (48 mg, single dose, in healthy volunteers).[1*]
Cmin	Not reported
AUC	50,800 ng•h/mL (48 mg, single dose, in healthy volunteers).[1]
Bioavailability	Undetermined; micronized fenofibrate > previous formulations.
Absorption	Tmax is 4-5 h. Absorption is increased when administered with food.
Protein Binding	~99%
Volume of Distribution	0.89 L/kg[2]
Renal Clearance	60% dose recovered in urine.
Renal Impairment	Fenofibrate should be initiated at 48 mg/day in mild-moderate renal impairment and only increased after review. Fenofibrate is contraindicated in severe renal impairment.
Hepatic Impairment	Administration in hepatic impairment has not been studied.

Metabolism and Distribution

Metabolized by	Esterases, *UGT2B7, UGT1A9, UGT1A3*[3].
Inducer of	Not reported.
Inhibitor of	*CYP2C9, CYP2C19, CPY2A6.*
Transported by	Not reported.

Italics denotes effect seen in vitro/animal studies only

* Plasma concentrations at steady state are approximately double those after a single dose.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

References

Unless otherwise stated (see below), information is from:

Fenofibrate Summary of Product Characteristics, Genus Pharmaceuticals, October 2024.

Ticor Prescribing Information, AbbVie Inc, November 2018.

1. Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver Disease. IR Younis, EJ Weber, C Nelson et al. J Clin Pharmacol. 2025, 65(7):850-859.
2. Clinical pharmacokinetics of fibric acid derivatives (fibrates). DB Miller & JD Spence. Clin Pharmacokinet. 1998, 34(2):155-162.
3. In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes. J Tojcic, M-O Benoit-Biancamano, MH Court et al. Drug Metab Dispos. 2009, 37(11):2236-43.

© Liverpool Drug Interactions Group, University of Liverpool, 3rd Floor William Henry Duncan Building, 6 West Derby Street, Liverpool, L7 8TX.

We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Liverpool and its servants or agents shall not be responsible or in any way liable for the continued currency of information in this publication whether arising from negligence or otherwise howsoever or for any consequences arising therefrom. The University of Liverpool expressly exclude liability for errors, omissions or inaccuracies to the fullest extent permitted by law.